Insider
AtriCure, Inc.ATRC

AtriCure announced goals for its BoxX-NoAF trial on preventing arrhythmia

On November 17, 2026, AtriCure announced details for its BoxX-NoAF clinical trial, which evaluates cardiac ablation and left atrial appendage exclusion (LAAE) to lower the risk of atrial fibrillation (Afib). The study targets patients with risk factors but no prior history of Afib.

Verified against 3 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
doctors doing surgery inside emergency room
Photo by Natanael Melchor on Unsplash

Key points

  • The BoxX-NoAF trial examines if combining cardiac ablation and LAAE during cardiac surgery effectively reduces new-onset Afib.
  • The study also analyzes whether post-operative Afib can be reduced after cardiac surgery.

Clinical trial goals and methodology

The BoxX-NoAF trial examines if combining cardiac ablation and LAAE during cardiac surgery effectively reduces new-onset Afib. The study targets patients predisposed to the condition who have no prior history of it.

Further research focus

The study also analyzes whether post-operative Afib can be reduced after cardiac surgery. Researchers are collecting data to determine the therapeutic value of preventive procedures in this patient group.

What to watch

Investors should watch for company updates on trial enrollment, a required step for results analysis. Future publication of clinical data in peer-reviewed journals or presentations at medical conferences are expected. No specific timeline for results is currently available.

Original sources

  1. Twitter-2122781954705682711November 17, 2026SHA-256 of our archived copy 27c6cd1ce985…
  2. LinkedIn-USA,ASIA,CANADA-urn:li:share:7528547657187938304November 17, 2026SHA-256 of our archived copy 30b0753c855a…
  3. Twitter-2122781967947108803November 17, 2026SHA-256 of our archived copy f0aef984b335…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards